Most drugs are intended to act on molecular targets residing within a specific tissue or cell
type. Therefore, the drug concentration within the target tissue or cells is most relevant to its …

Cisplatin is one of the most widely used anticancer agents for the treatment of solid tumors.
The clinical use of cisplatin is associated with dose‐limiting nephrotoxicity, which occurs in …

BACKGROUND AND PURPOSE The organic cation transporters 1 (OCT1) and 2 (OCT2)
mediate drug uptake into hepatocytes and renal proximal tubular cells, respectively …

Organic cation transporters (OCTs) of the solute carrier family (SLC) 22 and multidrug and
toxin extrusion (MATE) transporters of the SLC47 family have been identified as uptake and …

Introduction: Organic cation transporters collectively called OCTs belong to three gene
families (SLC22A1 OCT1, SLC22A2 OCT2, SLC22A3 OCT3, SLC22A4 OCTN1, SLC22A5 …

Cisplatin is a cytostatic drug used for treatment of solid organ tumors. The main adverse
effect is organic cation transporter 2 (OCT2)–mediated nephrotoxicity, observed in 30% of …

Introduction: Organic cation transporters OCT1, OCT2 and OCT3 expressed in the small
intestine, liver, brain and other organs play important roles in absorption, excretion and …

Purpose: Cisplatin is predominantly eliminated in the urine through active secretion. As the
solute carrier organic cation transporter 2 (OCT2) is highly expressed in the basolateral …

renal elimination of a number of cationic compounds is thought to be mediated by the
organic cation transporter 2 (OCT2, SLC22A2), a drug uptake transporter expressed at the …

The organic cation transporters (OCTs) OCT1, OCT2, OCT3, novel OCT (OCTN) 1, OCTN2,
multidrug and toxin exclusion (MATE) 1, and MATE kidney-specific 2 are polyspecific …